[A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide].

Problemy endokrinologii2025PMID: 41640144

Plain Language Summary

Russian expert working group consensus algorithm for personalized prescribing of tirzepatide (Tirzetta) and semaglutide (Velgia Eco) in patients with excess body weight, obesity, and T2DM, developed following a June 2025 Moscow meeting using available clinical evidence and expert opinion. Provides a decision framework for the Russian healthcare context where specific branded formulations are available. Delivers the first Russian consensus prescribing algorithm for semaglutide and tirzepatide—enabling evidence-based, personalized treatment selection for Russian endocrinologists and internal medicine physicians.

Abstract

On June 26, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the personalized approach of tirzepatide («Tirzetta®») and semaglutide («Velgia Eco®») in patients with excess body weight, obesity, and type 2 diabetes. Following the meeting, the objective was set to develop a consensus-based algorithm for prescribing these drugs to ensure their effective use in Russian clinical practice.

Authors

Troshina, E A; Antsiferov, M B; Ametov, A S; Galstyan, G R; Markova, T N; Romantsova, T I; Mazurina, N V; Koteshkova, O M